MetaCap

Candel Therapeutics (CADL) vs Fennec Pharmaceuticals (FENC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Fennec Pharmaceuticals (FENC) has outperformed Candel Therapeutics (CADL) over the past year, gaining 66.1% versus a gain of 10.8%. Over five years, FENC leads with a +35.8% price change compared with -48.5% for CADL. Fennec Pharmaceuticals is the larger company by market cap ($462.1 million vs $395.4 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CADL+10.77%FENC+66.12%
+214%+88%-38%
Nov 21, 20251 yearNov 20, 2026
CADL-53.63%FENC+33.23%
+40%-30%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CADL versus FENC key metrics
MetricCADLFENC
Share price$5.04$13.09
Market cap$395.37M$462.14M
1-day change-1.75%-2.68%
YTD return-10.80%+70.00%
1-year return+10.77%+66.12%
5-year return-48.47%+35.79%
P/E ratio (TTM)—436.33
Forward P/E—12.47
EPS (TTM)$-1.53$0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$44.64M
Revenue growth (YoY)—-6.09%
Net income (latest FY)$-38.18M$-9.74M
Operating margin—-14.07%
Net margin—-21.82%
52-week high$14.00$13.85
52-week low$4.35$5.65
Distance from 52-week high-64.00%-5.49%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+250.60%+34.45%
Average volume1.26M220.87K
Shares outstanding78.45M35.31M
Employees5535
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FENC has outperformed CADL by 55.3 percentage points over the past year.

About Candel Therapeutics

CADL stock →

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees

About Fennec Pharmaceuticals

FENC stock →

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees

CADL vs FENC FAQ

Which is bigger, Candel Therapeutics or Fennec Pharmaceuticals?

Fennec Pharmaceuticals (FENC) is larger, with a market capitalization of $462.14M compared with $395.37M for Candel Therapeutics (CADL).

Which stock has performed better over the past year, CADL or FENC?

FENC returned +66.12% over the past 12 months, compared with +10.77% for CADL (price return, excluding dividends). Past performance does not predict future results.

Are Candel Therapeutics and Fennec Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons